St Bartholomew's Hospital
London, EC1A 7BE, United Kingdom
NCT Number: NCT05938283
Pilot randomised trial to assess recruitment for a larger trial to compare the efficacy and adverse effects of the subcutaneous and transvenous ICD in patients with hypertrophic cardiomyopathy (HCM) and indication for ICD therapy, with no requirement for pacing
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
London, EC1A 7BE, United Kingdom
This study aims to test the feasibility of conducting a trial to investigate the use of subcutaneous implantable defibrillator (SICD) in patients with hypertrophic cardiomyopathy (HCM) and to determine whether SICD produces more complications than conventional, transvenous implantable defibrillator (TV ICD).
The primary analysis for the main trial is designed to test whether the S-ICD is non-inferior to the TV-ICD with respect to the primary endpoint of inappropriate shock treatment and complications. For the incidence of the primary endpoint statistical significance and 99% confidence intervals are calculated using Cox' proportional hazards model. Non-inferiority is considered to be established if the upper boundary of the one-sided 99% confidence interval did not exceed 1.92 (absolute difference < 12%).
Participant duration is expected to be 14 months. (12 months follow up post device implant) Recruitment duration expected to be 6-10 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation
Time frame: through study completion, expected at 10 months to 1 year
Assessment of rate of recruitment per month
Time frame: 12 months
Rate of inappropriate shocks and ICD related complications across the patients over a 12 month period.
Time frame: 12 months
% of patients who die
Time frame: 12 months
Major Adverse Cardiac Event (MACE), defined as cardiac death, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting and/or any valve surgery.
Time frame: 12 months
Rate over 12 months determined by IBHRE accredited Cardiac Scientist
Time frame: 12 months
Rate over 12 months determined by IBHRE accredited Cardiac Scientist
Time frame: 12 months
individually, defined as infections, bleedings, thrombotic events, pneumothorax, perforation/tamponade, lead reposition and lead- or device failures
Time frame: 12 months
Measured by admissions for Heart failure or unplanned outpatient appointments.
Time frame: 12 months
Amount of patients moving from SICD to TV group and visa versa over 12 month period.
Time frame: 12 months
Rate over 12 months determined by IBHRE accredited Cardiac Scientist
Time frame: 12 months
Scores for the different domains are converted and pooled using a scoring key, for a total score indicating a range of low to high QOL.
Time frame: 12 months
Scores for the different domains are converted and pooled using a scoring key, for a total score indicating a range of low to high QOL.
Time frame: 12 months
rate of patients with these events over a 12 month period
Time frame: 12 months
Time in months or days from implant to date of succesful therapy
Time frame: 12 months
% of first shocks that cardiovert ventricular arrhythmia
Time frame: Procedure duration- average of 2 hours expected
Duration of implant from needle to skin to skin closure.
Time frame: 12 months
Rate of patient hospitalisation for cardiac and non-cardiac causes over a 12 month period.
Time frame: Procedure duration- average of 2 hours expected
Amount of fluoroscopy required to complete implant procedure, expected fluoroscopy time of approximately 1 minute per patient.
Time frame: 12 months
% of patients that do not complete the sudy
Time frame: 12 months
% of data completed
Time frame: 12 months
% Of patients referred for recruitment was SICD screening making patients illegible. Either Yes or no.
Barts & The London NHS Trust
Other
Acronym: HICD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04141891
Acute Coronary Syndrome, Aortic Stenosis, Subvalvular
La Jolla, California, United States
View Trial DetailsNCT03210883
Cardiovascular Diseases, Heart Diseases
Los Angeles, California, United States
View Trial DetailsNCT03837574
Cardiovascular Abnormalities, Cardiovascular Diseases
Paris, France
View Trial DetailsNCT02976961
Behavior, Distress
Gentofte Municipality, Hellerup, Denmark
View Trial Details